肥胖与接受先进治疗的溃疡性结肠炎患者不良结局相关:来自美国的倾向匹配队列研究
该回顾性队列研究利用TriNetX数据库,比较肥胖(BMI≥30 kg/m2)与非肥胖(BMI 18.5-24.9)溃疡性结肠炎患者在接受先进治疗(TNFi、维得利珠单抗、乌司奴单抗、JAKi)后两年内复合结局(激素使用、治疗更换或结肠切除术)的风险差异。经1:1倾向评分匹配后,肥胖队列在各类先进治疗中复合结局风险均升高,提示肥胖与多种先进治疗疗效降低相关。
要点
- 肥胖溃疡性结肠炎患者使用TNFi、维得利珠单抗、乌司奴单抗或JAKi时复合结局风险均升高。
- 英夫利西单抗和阿达木单抗亚组分析同样显示肥胖患者复合结局风险升高。
- 研究为回顾性队列研究,结论提示肥胖与先进治疗疗效降低相关。
核心结论
- 肥胖与溃疡性结肠炎患者多种先进治疗疗效降低相关。
研究设计与样本
- 回顾性队列研究,利用TriNetX数据库,比较肥胖(BMI≥30 kg/m2)与非肥胖(BMI 18.5-24.9)溃疡性结肠炎患者。
- 肥胖队列中接受TNFi、维得利珠单抗、乌司奴单抗和JAKi的患者分别为3904例、2025例、1150例和477例。
- 采用1:1倾向评分匹配,匹配人口学特征、合并症、实验室值和包括激素在内的IBD药物。
主要发现
- 经倾向评分匹配后,肥胖队列相比对照队列复合结局风险升高:TNFi组aHR 1.37(95% CI 1.29-1.49),维得利珠单抗组aHR 1.29(95% CI 1.16-1.43),乌司奴单抗组aHR 1.1.26(95% CI 1.10-1.44),JAKi组aHR 1.38(95% CI 1.13-1.69)。
- 基于特定TNFi的亚组分析显示,英夫利西单抗组aHR 1.36(95% CI 1.22-1.52),阿达木单抗组aHR 1.26(95% CI 1.11-1.42),均为两年内复合结局风险升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity has been linked to a more severe phenotype in patients with ulcerative colitis (UC). AIM: To evaluate the impact of obesity on outcomes of advanced therapies in UC. METHODS: We conducted a retrospective cohort study utilising the TriNetX database comparing the composite score of corticosteroid use, change in advanced therapy or colectomy within two years between two cohorts of patients with UC-those with obesity (BMI ≥ 30 kg/m2) and those without (BMI 18.5-24.9). The risk assessment was stratified to specific advanced therapies, including tumour necrosis factor α inhibitors (TNFi), vedolizumab, ustekinumab and Janus kinase inhibitors (JAKi). We performed 1:1 propensity score matching (PSM) for demographics, co-morbid conditions, laboratory values and IBD medications including corticosteroids. RESULTS: There were 3904, 2025, 1150 and 477 patients on TNFi, vedolizumab, ustekinumab and JAKi, respectively, in the UC obesity cohort. After PSM, the UC obesity cohort was at an increased risk of the composite outcome of corticosteroid use, change in therapy and colectomy compared to the UC control cohort in patients on TNFi (aHR 1.37, 95% CI 1.29-1.49), vedolizumab (aHR 1.29, 95% CI 1.16-1.43), ustekinumab (aHR 1.1.26, 95% CI 1.10-1.44) and JAKi (aHR 1.38, 95% CI 1.13-1.69). Sub-group analysis based on the specific TNFi also showed an increased risk of composite outcome for infliximab (aHR 1.36, 95% CI 1.22-1.52) and adalimumab (aHR 1.26, 95% CI 1.11-1.42) within 2 years. CONCLUSIONS: Obesity is associated with lower efficacy of several advanced therapies in patients with UC.
引用
- Desai A, Sehgal P, Khataniar H, et al. Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S. Aliment Pharmacol Ther. 2025. PMID: 39844347. doi:10.1111/apt.18513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。